Cialis

Tadalafil — Research Overview

Tadalafil (trade name Cialis) is a highly selective phosphodiesterase type 5 (PDE5) inhibitor. It inhibits the PDE5 enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in smooth muscle cells, prolonging the vasodilatory effects of nitric oxide (NO). With a half-life of approximately 17.5 hours — significantly longer than sildenafil (~4–5 hours) or vardenafil (~4–5 hours) — tadalafil is a preferred research tool for studying sustained PDE5 inhibition.

Mechanism of Action

Nitric oxide (NO) activates guanylate cyclase, increasing intracellular cGMP levels. cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain kinase and causes smooth muscle relaxation and vasodilation. PDE5 degrades cGMP, terminating this effect. Tadalafil inhibits PDE5, maintaining elevated cGMP and prolonging smooth muscle relaxation in vascular and non-vascular tissues.

Research Applications

Tadalafil is studied across multiple research domains:

• Pulmonary arterial hypertension (PAH): Investigating PDE5-mediated remodeling in pulmonary vasculature
• Cardiovascular models: Studying NO-cGMP pathway in cardiac and systemic vascular biology
• Benign prostatic hyperplasia (BPH): Research on smooth muscle tone in the lower urinary tract
• Exercise physiology: PDE5 inhibition in skeletal muscle blood flow and oxygen delivery
• Cardiomyopathy models: Emerging research on tadalafil in Duchenne muscular dystrophy models
• Comparative PDE5 selectivity: Evaluating selectivity profiles across PDE isoforms

Selectivity Profile

Tadalafil is approximately 10,000-fold more selective for PDE5 over PDE1, PDE2, PDE3, and PDE4. Its selectivity over PDE6 (retinal) is lower (~700-fold) compared to sildenafil, which contributes to research interest in visual-pathway pharmacology comparisons.

Pharmacokinetic Profile

Oral bioavailability is approximately 15% with significant inter-individual variability. Tmax is 2 hours post-administration. Tadalafil is predominantly metabolized by CYP3A4 and is 94% protein-bound. The mean terminal half-life of ~17.5 hours supports once-daily dosing paradigms in research protocols requiring sustained steady-state PDE5 inhibition.

Supplied For

Research and preclinical laboratory use by qualified investigators under appropriate ethical and regulatory frameworks. Not for human consumption. Certificate of Analysis available upon request.